Platinum-Sensitive Ovarian Carcinoma — Trials

Platinum-Sensitive Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 7
Ph III recruiting: 2
Growth YoY: —
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05002868	Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors	completed	Phase 1	23	Rhizen Pharmaceuticals SAINDUSTRY	2	Sep 19, 2024	clinicaltrials
NCT02020707	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	completed	Phase 1	43	Mayo ClinicOTHER	1	Jul 26, 2024	clinicaltrials